Japan Quasi-Drug Registration For Imported Products: 2026 Regulatory Guide

Understanding Japan's Unique Quasi-Drug Regulatory Category

Japan maintains one of the world's most sophisticated regulatory systems for personal care, hygiene, and functional cosmetic products. A distinctive feature of this framework is the quasi-drug category, known locally as Iyaku-Bugaibuhin.

Positioned between conventional cosmetics and pharmaceutical products, quasi-drugs occupy a unique regulatory space. They are permitted to make limited functional and preventive claims while remaining subject to significantly greater regulatory oversight than ordinary cosmetics.

For international manufacturers seeking access to the Japanese market, understanding the requirements surrounding ingredient approvals, Marketing Authorization Holder (MAH) obligations, product claims, labeling standards, and regulatory submissions is essential.

This comprehensive guide from Maven Regulatory Solutions explains how imported quasi-drugs are registered in Japan, including PMDA review processes, MHLW requirements, GMP expectations, import obligations, and post-market compliance responsibilities.

What Are Quasi-Drugs in Japan?

Quasi-drugs are products containing approved active ingredients that provide specific preventive or functional benefits but do not meet the legal definition of pharmaceuticals.

These products may support:

• Disease prevention
• Hygiene maintenance
• Skin protection
• Functional skincare benefits
• Hair and scalp care
• Antibacterial applications
• Oral care functions
• Odor and perspiration control

Because they can make approved efficacy claims, quasi-drugs require pre-market authorization before commercialization.

Why The Quasi-Drug Category Matters

Japan's quasi-drug framework allows manufacturers to communicate benefits that are not permitted for standard cosmetics.

Examples Of Permitted Functional Benefits

Products making these claims generally cannot be marketed as ordinary cosmetics in Japan.

Regulatory Authorities Governing Quasi-Drugs

Several Japanese regulatory bodies oversee quasi-drug approval and compliance.

Key Regulatory Authorities

Together, these authorities ensure product quality, safety, efficacy, and ongoing market compliance.

Regulatory Framework for Quasi-Drugs

Imported quasi-drugs are regulated primarily under Japan's Pharmaceutical and Medical Device Act (PMD Act).

The framework governs:

• Product approval requirements
• Active ingredient control
• Manufacturing standards
• Advertising restrictions
• Labeling obligations
• Import procedures
• post-market surveillance activities

Manufacturers must demonstrate compliance before products may be sold within Japan.

Quasi-Drug Classification Pathways

The complexity of registration depends on the nature of the product and its active ingredients.

Main Registration Categories

Products utilizing previously approved active ingredients generally experience a more straightforward review process.

Products introducing new actives or novel efficacy claims undergo significantly more extensive scientific assessment.

Japan Quasi-Drug Registration Process for Imported Products

Registration follows a structured review pathway designed to evaluate product quality, safety, and regulatory compliance.

Step 1: Ingredient And Efficacy Assessment

Before submission, manufacturers must verify that active ingredients are acceptable for quasi-drug use.

Key Assessment Areas

• Active ingredient eligibility
• Permitted concentration ranges
• Intended claims validation
• Safety profile assessment
• Formula compliance review
• Restricted ingredient evaluation

Only approved efficacy claims may be used.

Claims extending beyond approved functional benefits may trigger pharmaceutical classification.

Step 2: Appointment Of A Marketing Authorization Holder (MAH)

A Japan-based Marketing Authorization Holder (MAH) is mandatory for imported quasi-drugs.

Foreign companies cannot independently hold product approvals in Japan.

MAH Responsibilities Include

• Regulatory submissions
• Product release oversight
• Quality management activities
• Regulatory communication with authorities
• Product recall management
• Adverse event reporting
• Market surveillance support

The MAH serves as the legal entity responsible for regulatory compliance within Japan.

Step 3: Dossier Preparation

A complete registration dossier must be compiled before submission.

Typical Documentation Requirements

Administrative Documents

• Application forms
• Applicant information
• MAH authorization documentation
• Manufacturing site details

Product Documentation

• Full formulation details
• Ingredient specifications
• Product specifications
• Manufacturing process information

Quality And Safety Documentation

• Stability studies
• Microbiological testing data
• Safety assessments
• Toxicological support data
• Quality control procedures

Manufacturing Documentation

• GMP evidence
• Manufacturing licenses
• Site qualification documentation
• Quality management records

A well-prepared dossier significantly reduces review delays.

Step 4: Regulatory Submission and Review

Applications are submitted through the MAH to the appropriate authority.

Depending on product type, review activities may involve:

• Administrative review
• Technical assessment
• Ingredient verification
• Labeling evaluation
• Safety assessment
• Quality review

PMDA Review Focus Areas

Authorities may issue requests for additional information during the review process.

Typical Approval Timeline

Actual timelines vary based on dossier quality and product complexity.

Step 5: Approval And Product Authorization

Upon successful completion of review activities, approval is granted.

Approval Outcomes

Manufacturers receive:

• Quasi-drug approval authorization
• Product approval number
• Commercialization authorization

The approval number becomes a mandatory element of product labeling.

Labeling And Packaging Requirements

Japan maintains strict labeling requirements for quasi-drugs.

Mandatory Label Information

Most information must appear in Japanese language format.

Advertising And Claims Restrictions

Claims are tightly controlled under Japanese regulations.

Permitted Claims

• Approved efficacy statements
• Preventive benefits within authorized scope
• Functional performance claims supported by approval

Prohibited Claims

• Cure claims
• Disease treatment claims
• Guaranteed results statements
• Pharmaceutical-level efficacy claims
• Misleading superiority claims

Non-compliant advertising may result in enforcement action even after product approval.

Customs And Import Requirements

Regulatory approval alone does not guarantee import clearance.

Imported quasi-drugs must satisfy customs and import documentation requirements.

Common Import Documents

• Product approval documentation
• Certificate of origin
• Commercial invoice
• Ingredient declaration
• Shipping documentation
• Manufacturer information

Incomplete documentation may result in shipment delays or rejection.

GMP Expectations for Imported Quasi-Drugs

Manufacturing facilities supplying Japan must demonstrate appropriate quality controls.

GMP Review Areas

• Manufacturing processes
• Personnel qualifications
• Facility controls
• Contamination prevention systems
• Documentation practices
• Quality assurance programs

Japanese authorities continue increasing focus on manufacturing oversight and data integrity.

Post-Market Compliance Obligations

Approval is only the beginning of regulatory responsibility.

Manufacturers and MAHs must maintain compliance throughout the product lifecycle.

Ongoing Regulatory Responsibilities

Authorities may conduct inspections or investigations at any time.

Why Compliance Challenges Arise for Foreign Manufacturers

International companies frequently encounter challenges when entering Japan.

Common Regulatory Obstacles

• Complex ingredient assessments
• Japanese-language documentation requirements
• MAH coordination challenges
• Label adaptation requirements
• Claim substantiation expectations
• Regulatory translation accuracy
• Import documentation management
• Post-market compliance obligations

Early planning significantly improves approval efficiency.

Emerging Regulatory Trends in Japan for 2026

Japan continues modernizing its regulatory oversight framework.

Key Regulatory Trends

• Increased scrutiny of whitening ingredients
• Enhanced sunscreen efficacy assessments
• Stronger GMP documentation reviews
• Digitalization of regulatory processes
• Expanded MAH accountability requirements
• Greater focus on evidence-based claims
• Increased post-market surveillance activities
• Supply chain transparency initiatives

Manufacturers should proactively monitor these developments to maintain compliance.

Strategic Considerations for Global Brands

Organizations planning market entry should develop a structured regulatory strategy.

Recommended Preparatory Activities

• Conduct ingredient compliance reviews
• Verify claim eligibility early
• Select qualified MAH partners
• Prepare Japanese-language labeling strategies
• Assess GMP readiness
• Develop post-market surveillance procedures

A proactive approach reduces regulatory risk and accelerates commercialization.

How Maven Regulatory Solutions Supports Japan Quasi-Drug Registration

Our Services

• Quasi-drug regulatory strategy development
• Ingredient eligibility assessments
• MAH coordination support
• Registration dossier preparation
• Labeling and claims review
• GMP compliance consulting
• PMDA response support
• Post-market compliance planning
• Regulatory intelligence monitoring

Why Choose Maven

• Global regulatory expertise
• Deep Asia-Pacific regulatory knowledge
• End-to-end registration support
• Science-based compliance strategies
• Practical commercialization guidance
• Up-to-date Japanese regulatory intelligence

Our team helps companies navigate Japan's complex quasi-drug framework efficiently and confidently.

Need Support with Japan Quasi-Drug Registration?

Whether you are preparing a new product launch, evaluating ingredient eligibility, coordinating with a Marketing Authorization Holder, or responding to PMDA questions, Maven Regulatory Solutions can support every stage of the registration process.

Contact Maven Regulatory Solutions For

• Japan quasi-drug registration strategy
• MAH partner coordination
• Product classification assessments
• Labeling and claims compliance reviews
• PMDA submission support
• GMP compliance consulting
• Import readiness assessments
• Post-market compliance management

Our experts help international brands achieve successful and sustainable access to the Japanese market.

Conclusion

Japan's quasi-drug category offers significant commercial opportunities for manufacturers seeking to market products with approved functional and preventive claims.

However, successful market entry requires careful navigation of ingredient restrictions, MAH obligations, PMDA review procedures, labeling requirements, GMP expectations, and post-market compliance responsibilities.

Organizations that proactively align their products with Japan's regulatory framework will be better positioned to:

• Accelerate approvals
• Reduce regulatory delays
• Improve compliance readiness
• Strengthening market access opportunities
• Maintain long-term regulatory success

As Japan continues strengthening oversight of functional personal care products, a robust regulatory strategy remains essential for sustainable commercialization.

Frequently Asked Questions 

Q1. What is a quasi-drug in Japan?

A quasi-drug is a regulated product category positioned between cosmetics and pharmaceuticals that allows specific approved functional claims.

Q2. Are sunscreens regulated as cosmetics in Japan?

Most sunscreens are regulated as quasi-drugs because they make approved UV protection claims.

Q3. Can foreign companies directly register quasi-drugs in Japan?

No. Imported quasi-drugs require a Japan-based Marketing Authorization Holder (MAH).

Q4. How long does quasi-drug registration take?

Approval timelines typically range from 4 to 12 months depending on product complexity and dossier quality.

Q5. Are efficacy claims flexible under Japanese regulations?

No. Only approved efficacy claims recognized by Japanese authorities may be used.

Q6. Is GMP evidence required for imported quasi-drugs?

Yes. Manufacturers must provide acceptable evidence demonstrating compliance with applicable quality standards.

Q7. How can Maven Regulatory Solutions support Japan registrations?

Maven provides regulatory strategy, MAH coordination, dossier preparation, labeling review, PMDA support, and post-market compliance consulting.